Industry Leading Phase 1 Capabilities

Moving quickly and safely through Phase I trials is critical for establishing your clinical development success. Our Phase I research capabilities feature 580 beds across five strategically located facilities on three continents.

All Phase I sites are staffed by expert Clinical Pharmacology Teams that routinely conduct hundreds of Phase I/IIa studies annually. We also have scientific expertise in the design of all types of Phase I studies, as well as the interpretation of study data. We specialize in conducting proof of concept (POC) studies in special and patient populations. We also develop pharmacodynamic endpoints and laboratory biomarker assays for the evaluation of your early stage compounds, targeted for a wide variety of therapeutic indications.

QPS has one of the world’s largest Phase I site offerings with more than 650 Phase I beds on three continents:

• 240 in Springfield, Missouri, USA
• 40 in Taipei, Taiwan
• 100 in Taizhou, China
• 95 in Miami, Florida, USA
• 138 in Hyderabad, India
• 60 in Suzhou, China
• 58 in Groningen, The Netherlands
• 8 in Leeuwarden, The Netherlands

In addition to one of the world’s largest Phase I site offerings, we provide fully integrated services to seamlessly move your project through early clinical development. Our expert staff use disciplined processes to supply accurate, superior-quality data so you can make confident decisions – earlier and faster.